14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
×
Home
/
Stock Analysis
/
Compare Terminal
/
HCM vs AVDL
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
HCM vs AVDL: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
AVDL Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–3 Matrix Metrics)
AVDL Overall Winner
6-Pillar Tally: HCM 1 – 4 AVDL (1 Tie)
Matrix Metrics: HCM 3 – 7 AVDL
As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) is the stronger overall head-to-head candidate over HUTCHMED (China) Limited (HCM) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HCM carries a Unified Composite Score of 38.1/100 (SELL) at $13.22 (N/M Forward P/E, -6.3% operating margin), whereas AVDL carries 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin).
HCM
NASDAQ
HUTCHMED (China) Limited American Depositary Shares
Pharmaceutical Preparations
Market Cap
$2.3B
TTM Revenue
$549M
Forward P/E
N/M
Beta / 30D Vol
0.64β · 45% Vol
Unified Composite Score
38.1 / 100
SELL
Tech 31.0
Fund 44.0
Flow 50.0
Mom 56.0
Weinstein Technical Phase
Neutral · Hold
Mixed signals - no dominant trend phase, RSI 39
RSI-14: 38.5 · SMA20: $14.15 · SMA50: $14.11
AVDL
NASDAQ
Head-to-Head Winner
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
Market Cap
$2.1B
TTM Revenue
$249M
Forward P/E
28.8x
Beta / 30D Vol
0.14β · 2% Vol
Unified Composite Score
62.9 / 100
BUY
Tech 75.0
Fund 60.0
Flow 50.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 62
RSI-14: 62.3 · SMA20: $21.56 · SMA50: $21.50
6-Pillar Scorecard Institutional Category Breakdown (HCM 1 – 4 AVDL)
Columns: Metric · HCM · AVDL
1. Valuation Multiples
AVDL
Forward P/E
N/M
28.8x
Trailing P/E
134.0x
16.8x
PEG Ratio
N/M
0.07x
EV / Revenue
4.2x
8.5x
2. Growth & Scale
AVDL
Revenue Growth (YoY)
+0.2%
+54.9%
Earnings Growth (YoY)
-96.5%
+0.0%
TTM Revenue (USD)
$549M
$249M
Market Cap
$2.3B
$2.1B
3. Profitability & Quality
AVDL
Gross Margin
13.3%
94.9%
Operating Margin
-6.3%
2.5%
Net Profit Margin
3.3%
-0.1%
Return on Equity (ROE)
1.5%
-0.3%
4. Balance Sheet & Cash Flow
AVDL
Cash Generation (TTM)
-$21M EBITDA
$2.7M EBITDA
Cash Flow Margin
-3.7% EBITDA Mgn
1.1% EBITDA Mgn
Net Cash / Leverage
$7.25 Book/Sh · 1.5% ROE
$1.01 Book/Sh · -0.3% ROE
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
Tie
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
82.7% (73rd %ile)
2.4% (<1st %ile)
Put/Call OI Skew
Thin ADR Chain
N/A
OBV Trend / Tech Phase
NEUTRAL · Neutral
NEUTRAL · Markup
6. R&D & Supply-Chain Moat
HCM
OpEx & R&D Intensity
19.6% of Rev ($108M)
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Drug Manufacturers - Specialty & Generic Operator
Drug Manufacturers - Specialty & Generic Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: HCM (3) vs AVDL (7)
Institutional Metric
HCM
AVDL
Criterion
Row Edge
Market Capitalization
Scale
$2.3B
$2.1B
Larger Scale
HCM
Trailing P/E Ratio
Valuation
134.0x
16.8x
Lower Multiple
AVDL
Forward P/E Ratio
Valuation
N/M
28.8x
Lower Multiple
AVDL
Revenue Growth (YoY)
Growth
+0.2%
+54.9%
Higher Growth
AVDL
Operating Margin (TTM)
Profitability
-6.3%
2.5%
Higher Margin
AVDL
Net Profit Margin
Profitability
3.3%
-0.1%
Higher Margin
HCM
Return on Equity (ROE)
Capital Efficiency
1.5%
-0.3%
Higher ROE
HCM
52-Week Range Position
Momentum
53% ($10–$16)
89% ($6–$24)
Stronger Trend
AVDL
Beta / 30D Volatility
Risk Regime
0.64β · 45% Vol
0.14β · 2% Vol
Lower Realized Risk
AVDL
Unified Institutional Score
Composite Signal
38.1 / 100 (SELL)
62.9 / 100 (BUY)
Higher Composite
AVDL
Trailing 12M Revenue (USD)
Operating Scale
$549M
$249M
FX-Normalized USD
Scale
Gross Profit Margin (TTM)
Unit Pricing Power
13.3%
94.9%
Higher Margin
Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 4.2x EV/Rev
0.07x PEG · 8.5x EV/Rev
Lower Multiple
Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$21M EBITDA ($7.25 Book/Sh · 1.5% ROE)
$2.7M EBITDA ($1.01 Book/Sh · -0.3% ROE)
Higher Cash / Net Cash
Solvency
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M
3M
6M
1Y
1M Horizon
HCM +0.56 pp
HCM:
+1.21%
·
AVDL:
+0.65%
3M Horizon
HCM +8.74 pp
HCM:
+3.07%
·
AVDL:
-5.67%
6M Horizon
HCM +8.74 pp
HCM:
+3.07%
·
AVDL:
-5.67%
1Y Horizon
HCM +8.74 pp
HCM:
+3.07%
·
AVDL:
-5.67%
Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)
Split-Invariant USD Revenue & Operating Margin (%)
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HCM vs AVDL. Trailing 12-month operating profitability (HCM -6.3% vs AVDL 2.5%) and valuation multiples (HCM N/M vs AVDL 28.8x Forward P/E) are benchmarked directly in Pillar 4 below.
HCM ADR TTM Benchmark
FX-Normalized USD
TTM Revenue $549M
Gross Margin 13.3%
Op. Margin -6.3%
ROE / Fwd P/E 1.5% · N/M
AVDL ADR TTM Benchmark
FX-Normalized USD
TTM Revenue $249M
Gross Margin 94.9%
Op. Margin 2.5%
ROE / Fwd P/E -0.3% · 28.8x
HCM
UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV
82.7%
IV Percentile
73rd %ile
Put/Call OI Skew
Thin ADR Chain
IV Regime
Elevated (60th–80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
AVDL
UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV
2.4%
IV Percentile
<1st %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
HCM Moat Profile
Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.3B market capitalization and -6.3% operating margin.
OpEx & R&D Reinvestment
19.6% of Rev ($108M)
90D Engineering Disclosures
0 Published
AVDL Moat Profile
Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.1B market capitalization and 2.5% operating margin.
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ HCM vs AVDL Key Questions & Quantitative Answers
Is HCM or AVDL a better stock to buy right now?
As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) is the stronger overall head-to-head candidate over HUTCHMED (China) Limited (HCM) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HCM carries a Unified Composite Score of 38.1/100 (SELL) at $13.22 (N/M Forward P/E, -6.3% operating margin), whereas AVDL carries 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin). Technically, HCM sits in a Neutral phase (RSI 38.5, UNCLASSIFIED options structure) and AVDL sits in a Markup phase (RSI 62.3, UNCLASSIFIED options structure).
Does HCM or AVDL have stronger revenue and earnings growth?
AVDL leads the Growth & Scale pillar: HCM posts +0.2% YoY revenue growth and -96.5% YoY earnings growth on $549M TTM revenue (13.3% gross margin, -6.3% operating margin), compared with AVDL at +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin). On trailing 12-month operating scale, HCM generates $549M in USD-normalized revenue versus $249M for AVDL. In operating R&D and SG&A reinvestment, HCM deploys 19.6% of Rev ($108M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AVDL.
Is HCM or AVDL cheaper on valuation?
AVDL screens cheaper on headline valuation multiples. HCM trades at N/M Forward P/E, 134.0x Trailing P/E, N/M PEG, and 4.2x EV/Revenue (-3.7% EBITDA margin), whereas AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HCM (1.5% ROE) versus AVDL (-0.3% ROE) capital efficiency.
How is options market volatility positioned on HCM vs AVDL?
In options market volatility and institutional positioning, HCM carries 82.7% implied volatility (73rd %ile, Elevated (60th–80th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.64β · 45% Vol realized risk). By comparison, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk).
HUTCHMED (China) Limited American Depositary Shares (HCM) Research Suite
Avadel Pharmaceuticals plc Ordinary Share (AVDL) Research Suite
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.